24 Results for "

hepatic insulin resistance

" in MedChemExpress (MCE) Product Catalog:
Products (24)

24 Results for "hepatic insulin resistance" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-N2118
CAS No.: 521-32-4
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N6869
CAS No.: 1740-19-8
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-116538
CAS No.: 2420-56-6
Purity:  99.10%
Synonyms: trans-10,cis-12 CLA2
(10E,12Z)-Octadeca-10,12-dienoic acid (trans-10,cis-12 CLA2) is an orally active PPARα activator and inhibits adipocyte differentiation. (10E,12Z)-Octadeca-10,12-dienoic acid and its downstream metabolites have various antioxidant and antitumor activities. (10E,12Z)-Octadeca-10,12-dienoic acid can induce proinflammatory cytokines and chemokines, which would lead to decreased adipogenesis and insulin resistance in adipose tissue. (10E,12Z)-Octadeca-10,12-dienoic acid can affect many aspects of milk fat synthesis. (10E,12Z)-Octadeca-10,12-dienoic acid reduces expression of lipogenic enzymes and inhibits the desaturation of fatty acids. (10E,12Z)-Octadeca-10,12-dienoic acid can reduce lipoprotein lipase (LPL) activity in cultured 3T3-L1 adipocytes and enhance triacylglycerol release from these cells. (10E,12Z)-Octadeca-10,12-dienoic acid decreases the expression of hepatic stearoyl-CoA desatyrase mRNA in mice. (10E,12Z)-Octadeca-10,12-dienoic acid is associated with changes in mucosal NF-κB and Cyclin D1 protein levels in mice .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N2421
CAS No.: 523-92-2
Synonyms: 5-O-Methyl-myo-inositol
Sequoyitol (5-O-Methyl-myo-inositol) is an orally active hypoglycemic agent and antioxidant. Sequoyitol can be isolated from herbaceous plants. Sequoyitol downregulates the expression of NF-κB and TGF-β1, reduces ROS production and malondialdehyde levels, and enhances total antioxidant capacity. Sequoyitol activates the insulin signaling pathway, including the phosphorylation of IR, IRS1 and Akt. Sequoyitol increases serum insulin levels, inhibits hepatic glucose production, and promotes cellular glucose uptake. Sequoyitol antagonizes TNFα-induced inhibition of the insulin signaling pathway, and decreases blood urea nitrogen and serum creatinine levels. Sequoyitol elicits potential peaks in the chemosensors of adult and larval Atrophaneura alcinous, and acts as an oviposition stimulant for female Atrophaneura alcinous. Sequoyitol can be used in research related to type 2 diabetes, insulin resistance, hyperglycemia, impaired glucose tolerance and diabetic nephropathy .
loading...
    loading...
Cat. No.: HY-125848
CAS No.: 62025-49-4
Purity:  99.95%
Ginsenoside F2 is an orally active bioactive compound that participates in the regulation of metabolism and inflammation. Ginsenoside F2 promotes the phosphorylation of AMPK and ACC, binds to PPARγ, inhibits the phosphorylation of MAPK, activates the PI3K/AKT/GSK-3β pathway, reduces GLRX expression, and regulates lipid metabolism. Ginsenoside F2 reduces ROS production and MDA levels, restores SOD activity in cells, and alleviates oxidative stress. Ginsenoside F2 induces cell apoptosis (Apoptosis) and increases the number of cleaved caspase-3-positive cells. Ginsenoside F2 reduces body weight gain, adipose tissue weight and serum lipid levels in obese mice, and activates the hepatic AMPK signaling pathway and the expression of antioxidant enzymes. Ginsenoside F2 alleviates atopic dermatitis in mice by inhibiting inflammation and reshaping the gut microbiota . Ginsenoside F2 is applicable to research related to insulin resistance, obesity, atopic dermatitis, liver cancer, glioblastoma and glioma .
loading...
    loading...
Cat. No.: HY-160912
CAS No.: 1135000-36-0
Target:  

ELOVL

Research Areas:  

Metabolic Disease

ELOVL6-IN-5 is an orally active and selective elongase enzyme of long-chain fatty acid family 6 (ELOVL6) inhibitor with IC50 values of 85 nM and 38 nM for human and mouse ELOVL6, respectively. ELOVL6-IN-5 shows >60-fold selectivity over other ELOVL family enzymes (ELOVL1, 2, 3, 5) and no effect on other lipid synthesis enzymes like ACC1, ACC2. ELOVL6-IN-5 reduces hepatic fatty acid composition ratio of C18 to C16 in diet-induced obesity (DIO) and KKAy mice. ELOVL6 inhibition by ELOVL6-IN-5 does not improve insulin resistance. ELOVL6-IN-5 can be used for the research of metabolic disease .
loading...
    loading...
Cat. No.: HY-P1123
CAS No.: 87272-20-6
MEDICA16 is an orally active acetyl-CoA carboxylase and ATP-citrate lyase inhibitor. MEDICA16 limits the acetyl-CoA supply for acetyl-CoA carboxylase, inhibits acetyl-CoA carboxylase activity, exerts citrate-competitive inhibitory effects on ATP-citrate lyase, and reduces hepatic AMPK activity. MEDICA16 can be used in research related to insulin resistance, hyperlipidemia, and obesity .
loading...
    loading...
Cat. No.: HY-W009417
CAS No.: 77-54-3
Cedryl acetate is an orally active α-glucosidase inhibitor with an IC50 of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome .
loading...
    loading...
Cat. No.: HY-W109613
CAS No.: 1235-74-1
Methyl dehydroabietate is an orally active resin acid. Methyl dehydroabietate disrupts microbial cell walls and exhibits significant antibacterial activity. Methyl dehydroabietate induces the expression of PPARα in the liver and PPARγ in adipose tissue, and promotes adipocyte differentiation. Methyl dehydroabietate improves insulin resistance, reduces TNFα levels, and alleviates adipocyte hypertrophy and hepatic steatosis in obese mice. Methyl dehydroabietate can be used in research related to obesity, insulin resistance and hepatic steatosis .
loading...
    loading...
Cat. No.: HY-W127601
CAS No.: 8016-28-2
Lard oil is an orally active biochemical reagent. Lard oil upregulates PERK, eIF2a, CHOP, OPN, TLR2, TLR4, TNF-α, and downregulates GRP78 and IRE1a. Lard oil induces responses such as body fat accumulation, elevated serum insulin levels, increased HOMA-IR, hepatic ectopic lipid deposition, hepatic endoplasmic reticulum stress, and hepatic inflammation. Lard oil can be used in studies related to diet-induced obesity, insulin resistance, and non-alcoholic fatty liver disease .
loading...
    loading...
Cat. No.: HY-151959
CAS No.: 3025841-47-5
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
loading...
    loading...
Cat. No.: HY-144035
CAS No.: 2401894-26-4
Purity:  99.77%
Target:  

GCGR

GLP-1R agonist 4 is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 can be used for the research of type 2 diabetes mellitus, obesity, non-alcoholic steatohepatitis, insulin resistance and etc .
loading...
    loading...
Cat. No.: HY-23199
CAS No.: 1060438-30-3
Target:  

Acyltransferase

Research Areas:  

Metabolic Disease

H2-003 is a diacylglycerol acyltransferase DGAT2 inhibitor with an IC50 value of 7.4 μM against human targets. H2-003 reduces triacylglycerol biosynthesis and inhibits lipid droplet formation. H2-003 can be used in studies related to hepatic steatosis and insulin resistance .
loading...
    loading...
Cat. No.: HY-N2953
CAS No.: 151200-49-6
Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue .
loading...
    loading...
Cat. No.: HY-19176
CAS No.: 159978-02-6
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

S-15261 is an orally active and potent anti-hyperglycemic agent. S-15261 reduces hepatic glucose production through direct and insulin-sensitizing effects. S-15261 can be used for the research of insulin resistance syndrome .
loading...
    loading...
Cat. No.: HY-N2118R
CAS No.: 521-32-4
Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
loading...
    loading...
Cat. No.: HY-N6869R
CAS No.: 1740-19-8
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
loading...
    loading...
Cat. No.: HY-123765
CAS No.: 701232-94-2
Target:  

Acyltransferase

Research Areas:  

Metabolic Disease

JTT-553 is a DGAT1 inhibitor (IC50: 2.38 nM). JTT-553 reduces plasma concentrations of glucose, insulin, non-esterified fatty acids (NEFA), total cholesterol (TC), and hepatic triglycerides (TG). JTT-553 improves insulin-dependent glucose uptake and glucose intolerance in adipose tissue of DIO mice. JTT-553 reduces TNF-α mRNA levels and increases GLUT4 mRNA levels in adipose tissue of KK-Ay mice. JTT-553 improves adipose tissue insulin resistance and systemic glucose metabolism by reducing body weight. JTT-553 can be used in the study of obesity and type 2 diabetes mellitus (T2DM) .
loading...
    loading...
Cat. No.: HY-W009417R
CAS No.: 77-54-3
Cedryl acetate (Standard) is the analytical standard of Cedryl acetate. This product is intended for research and analytical applications. Cedryl acetate is an orally active α-glucosidase inhibitor with an IC50 of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome .
loading...
    loading...
Cat. No.: HY-161926
CAS No.: 2835447-74-8
Target:  

PPAR

Research Areas:  

Metabolic Disease

YGT-31 is a modulator for PPARγ with an IC50 of 1.72 μM, and a Ki of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model .
loading...
    loading...